Isabelle Vande Broek
Overview
Explore the profile of Isabelle Vande Broek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delforge M, Vekemans M, Depaus J, Meuleman N, Velde A, Vande Broek I, et al.
Hemasphere
. 2022 Dec;
6(12):e813.
PMID: 36479545
No abstract available.
2.
Heestermans R, De Brouwer W, Maes K, Vande Broek I, Vaeyens F, Olsen C, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230824
The analysis of bone marrow (BM) samples in multiple myeloma (MM) patients can lead to the underestimation of the genetic heterogeneity within the tumor. Blood-derived liquid biopsies may provide a...
3.
Janssens A, Berneman Z, Offner F, Snauwaert S, Mineur P, Vanstraelen G, et al.
Clin Hematol Int
. 2022 Oct;
4(4):133-143.
PMID: 36227519
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) in Belgium....
4.
Faict S, Oudaert I, dAuria L, Dehairs J, Maes K, Vlummens P, et al.
Cancers (Basel)
. 2019 Nov;
11(12).
PMID: 31756922
Multiple myeloma (MM) is well-known for the development of drug resistance, leading to relapse. Therefore, finding novel treatment strategies remains necessary. By performing a lipidomics assay on MM patient plasma,...
5.
Meers S, Bailly B, Vande Broek I, Malfait B, Van Hoorenbeeck S, Geers J, et al.
Acta Clin Belg
. 2019 Sep;
76(2):98-105.
PMID: 31551014
: Currently, there is no standard treatment for patients with acute myeloid leukaemia (AML) ineligible for standard induction chemotherapy (IC). This study aimed to report real-world evidence data on the...
6.
Decoster L, Vande Broek I, Neyns B, Majois F, Baurain J, Rottey S, et al.
Anticancer Res
. 2015 Dec;
35(12):6893-9.
PMID: 26637913
Aim: To investigate the efficacy of sunitinib in patients with advanced melanoma and to correlate angiogenic biomarkers with response and survival. Patients And Methods: We performed a phase II study...
7.
Xu S, Santini G, de Veirman K, Vande Broek I, Leleu X, De Becker A, et al.
PLoS One
. 2013 Nov;
8(11):e79752.
PMID: 24223191
Previous studies have demonstrated that mesenchymal stem cells from multiple myeloma (MM) patients (MM-hMSCs) display a distinctive gene expression profile, an enhanced production of cytokines and an impaired osteogenic differentiation...
8.
Vande Broek I, Jacobs P
Transfus Apher Sci
. 2013 Oct;
49(2):147-50.
PMID: 24074557
Major therapeutic advances in the treatment of multiple myeloma (MM) have dramatically improved response rate, remission duration and overall survival. These advances include the introduction of high-dose therapy plus autologous...
9.
Caers J, Vekemans M, Bries G, Beel K, Delrieu V, Deweweire A, et al.
Ann Med
. 2013 Jun;
45(5-6):413-22.
PMID: 23767978
The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a...
10.
Xu S, de Veirman K, Evans H, Santini G, Vande Broek I, Leleu X, et al.
Acta Pharmacol Sin
. 2013 Apr;
34(5):699-709.
PMID: 23564084
Aim: Vorinostat, a histone deacetylase (HDAC) inhibitor currently in a clinical phase III trial for multiple myeloma (MM) patients, has been reported to cause bone loss. The purpose of this...